20,162 Shares in Danaher Corporation $DHR Purchased by Mystic Asset Management Inc.

Key Points

• Mystic Asset Management acquired 20,162 Danaher shares worth approximately $4.47 million, making DHR about 1% of the firm’s portfolio. Institutional investors collectively own 79.05% of Danaher.
• Danaher exceeded quarterly expectations, reporting $1.94 in EPS and $6.26 billion in revenue, while revenue increased 5.5% year over year. The company also declared a quarterly dividend of $0.40 per share, equal to a 0.7% annualized yield.
• Analysts maintain a broadly positive view, with a consensus “Moderate Buy” rating and a $235.41 price target. Danaher is also pursuing AI growth through a collaboration with NVIDIA and plans to launch an AI-powered autonomous laboratory targeted for early 2027.

Mystic Asset Management Inc. purchased a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 20,162 shares of the conglomerate's stock, valued at approximately $4,467,000. Danaher comprises about 1.0% of Mystic Asset Management Inc.'s holdings, making the stock its 22nd largest holding.

Several other institutional investors have also recently made changes to their positions in DHR. BlackRock Inc. acquired a new position in Danaher in the second quarter valued at approximately $10,492,520,000. Wellington Management Group LLP increased its stake in Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC acquired a new stake in Danaher during the second quarter worth $1,456,317,000. Generation Investment Management LLP purchased a new stake in Danaher in the second quarter valued at $1,287,949,000. Finally, Bank of America Corp DE purchased a new stake in Danaher in the second quarter valued at $993,846,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Price Performance

Shares of DHR opened at $231.52 on Friday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The firm's fifty day simple moving average is $213.55 and its 200-day simple moving average is $195.74.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher's revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 EPS. Equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher's payout ratio is 28.42%.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Weiss Ratings raised Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, September 16th. Morgan Stanley raised their price objective on Danaher from $220.00 to $240.00 and gave the stock an "overweight" rating in a research report on Monday. Guggenheim raised their price objective on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. UBS Group initiated coverage on shares of Danaher in a research note on Wednesday, September 9th. They issued a "buy" rating and a $250.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $235.41.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.